lncRNA MALAT1 potentiates the progression of tongue squamous cell carcinoma through regulating miR-140-5p-PAK1 pathway

被引:36
|
作者
Zhu, Minhui [1 ]
Zhang, Caiyun [1 ]
Chen, Donghui [1 ]
Chen, Shicai [1 ]
Zheng, Hongliang [1 ]
机构
[1] Second Mil Med Univ, Changhai Hosp, Dept Otorhinolaryngol Head & Neck Surg, 168 Changhai Rd, Shanghai 200433, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2019年 / 12卷
基金
中国国家自然科学基金;
关键词
tongue squamous cell carcinoma; lncRNA; MALAT1; miRNA-140-5p; PAK1; NONCODING RNA; HEPATOCELLULAR-CARCINOMA; CANCER STATISTICS; INVASION; GROWTH; MICRORNA-140-5P; METASTASIS;
D O I
10.2147/OTT.S192069
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Tongue squamous cell carcinoma (TSCC) is the second most common malignancy in oral carcinoma. lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was regarded as an oncogcnic factor in various carcinomas. However, its underlying molecular mechanisms in the development and progression of TSCC have not been well featured till now. Methods: The expressions of MALAT1, miR-140-5p and p21 (RAC1)-activated kinase 1 (PAK1) mRNA were measured by RT-qPCR assay. The protein level of PAK1 was determined by western blot analysis. Cell viability was detected by Cell Counting Kit-8 assay. Transwell chamber was used to detect cell migratory and invasive capability. Luciferase reporter assay, RNA-binding protein immunoprecipitation (RIP) assay and biotin pull-down assay were applied to evaluate the relationship between MALAT1,miR-140-5p and PAK1. Xenograft experiments were performed to assess the effect and mechanism of MALAT1 in TSCC tumor growth. Results: The expression ofMALAT1 and p21 (RAC1)-activated kinase 1 (PAK1) was upregulated and micro RN A-140-5p (miR-140-5p) expression was downregulated in TSCC tissues and cells. MALAT1 knockdown induced miR-140-5p expression by direct interaction. Moreover, MALAT1 knockdown inhibited proliferation, migration, and invasion by upregulating miR-140-5p expression in TSCC cells. Additionally, PAK1 was identified as a direct target of miR-140-5p. Also, MALAT1 knockdown inhibited PAK1 expression by upregulating miR-140-5p in TSCC cells. Furthermore, miR-I40-5p overexpression curbed the proliferation, migration, and invasion of TSCC cells by targeting PAK1. Finally, MALAT1 knockdown inhibited tumor growth by upregulating miR-140-5p and downregulating PAK1 in mouse xenograft models of TSCC. Conclusion: MALAT1 contributed to TSCC progression via miR-140-5p-PAK1 regulatory axis, highlighting a potential target for TSCC management.
引用
收藏
页码:1365 / 1377
页数:13
相关论文
共 50 条
  • [21] MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1
    Wei, Zhenxing
    Chang, Kunpeng
    Fan, Chongsheng
    Zhang, Yang
    CANCER CELL INTERNATIONAL, 2020, 20 (01)
  • [22] LncRNA MALAT1 acts as a miR-125a-3p sponge to regulate FOXM1 expression and promote hepatocellular carcinoma progression
    Liu, Shihai
    Qiu, Jing
    He, Guifang
    Liang, Ye
    Wang, Liping
    Liu, Changchang
    Pan, Huazheng
    JOURNAL OF CANCER, 2019, 10 (26): : 6649 - 6659
  • [23] LncRNA PVT1 promotes malignant progression by regulating the miR-7-5p/CDKL1 axis in oral squamous cell carcinoma
    Li, Jun
    Ding, Shuxin
    Li, Min
    Zou, Bo
    Chu, Miaomiao
    Gu, Guohao
    Chen, Cheng
    Liu, Yu-jiao
    Zheng, Ke
    Meng, Zhen
    MOLECULAR AND CELLULAR PROBES, 2024, 78
  • [24] The lncRNA MALAT1 participates in regulating coronary slow flow endothelial dysfunction through the miR-181b-5p-MEF2A-ET-1 axis
    Zhao, Cuiting
    Zong, Zhihong
    Zhu, Qing
    Wang, Yonghuai
    Li, Xinxin
    Zhang, Chenghong
    Ma, Chunyan
    Xue, Yixue
    VASCULAR PHARMACOLOGY, 2021, 138
  • [25] Expression of Concern: Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma
    Wang, Zhujuan
    Chang, Xiong
    Zhu, Guannan
    Gao, Xiaoting
    Chang, Luyuan
    CELL CYCLE, 2022, 21 (01) : 105 - 105
  • [26] LncRNA MALAT1 inhibits the proliferation and invasiveness of laryngeal squamous cell carcinoma Hep-2 cells by modulating miR-362-3p
    Xie, Baotong
    Wang, Zhaohua
    Li, Tao
    Xue, Junfang
    Zhang, Chunming
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (06): : 3729 - 3740
  • [27] LncRNA MALAT1 promotes neuropathic pain progression through the miR-154-5p/AQP9 axis in CCI rat models
    Wu, Jianping
    Wang, Chuanguang
    Ding, Haiyang
    MOLECULAR MEDICINE REPORTS, 2020, 21 (01) : 291 - 303
  • [28] miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma
    Tao, Fangfang
    Tian, Xinxin
    Ruan, Shanming
    Shen, Minhe
    Zhang, Zhiqian
    FASEB JOURNAL, 2018, 32 (11): : 6330 - 6343
  • [29] LncRNA MALAT1 mediates osteogenic differentiation in osteoporosis by regulating the miR-485-5p/WNT7B axis
    Zhou, Yuan
    Xu, Zhuo
    Wang, Yuanyi
    Song, Qiang
    Yin, Ruofeng
    FRONTIERS IN ENDOCRINOLOGY, 2023, 13
  • [30] Suppression of lncRNA MALAT1 by betulinic acid inhibits hepatocellular carcinoma progression by targeting IAPs via miR-22-3p
    Chen, Feiyu
    Zhong, Zhangfeng
    Tan, Hor Yue
    Guo, Wei
    Zhang, Cheng
    Cheng, Chien-Shan
    Wang, Ning
    Ren, Junguo
    Feng, Yibin
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (06):